Drug Profile
Methylphenidate extended-release/abuse-resistant - Collegium Pharmaceutical
Alternative Names: COL 171Latest Information Update: 28 Jun 2022
Price :
$50
*
At a glance
- Originator Collegium Pharmaceutical
- Class Behavioural disorder therapies; Neuroprotectants; Nootropics; Phenylacetates; Piperidines; Sleep disorder therapies; Small molecules
- Mechanism of Action Central nervous system stimulants; Dopamine release stimulants; Dopamine uptake inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Attention-deficit hyperactivity disorder
Most Recent Events
- 28 Jun 2022 No recent reports of development identified for preclinical development in Attention-deficit-hyperactivity-disorder in USA (PO, Controlled release)
- 01 Jun 2018 Chemical structure information added
- 28 May 2018 Preclinical development for Attention-deficit hyperactivity disorder is ongoing in USA (PO) (Collegium Pharmaceutical pipeline, May 2018)